Abstract
Chemokines and their receptors have a multifaceted role in tumor biology and are implicated in nearly all aspects of cancer growth, survival and dissemination. Modulation of the interaction between chemokines and their cell surface receptor is, therefore, a promising area for the development of new cancer medicines. In this review, we look at the compelling evidence that is emerging to support targeting CXC chemokines, also known as family α chemokines, as novel therapeutic strategies in the treatment of cancer.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Animals
-
Antineoplastic Agents / chemistry
-
Antineoplastic Agents / pharmacology
-
Antineoplastic Agents / therapeutic use*
-
Chemokines, CXC / genetics
-
Chemokines, CXC / immunology*
-
Drug Discovery / methods
-
Gene Expression Regulation, Neoplastic / drug effects
-
Humans
-
Molecular Targeted Therapy / methods*
-
Neoplasms / drug therapy*
-
Neoplasms / genetics
-
Neoplasms / immunology
-
Receptors, CXCR / genetics
-
Receptors, CXCR / immunology*
-
Small Molecule Libraries / chemistry
-
Small Molecule Libraries / pharmacology
-
Small Molecule Libraries / therapeutic use*
Substances
-
Antineoplastic Agents
-
Chemokines, CXC
-
Receptors, CXCR
-
Small Molecule Libraries